Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSPPC-96 Vaccine with Temozolomide in Newly Diagnosed Glioblastoma
NCT00905060Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Jun 2009
- Primary completion
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vitespen in glioblastoma multiforme (GBM), sponsored by University of California, San Francisco. Started Jun 2009; status: completed.
02
Drugs
vitespen
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00905060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00905060.